← Eichor
Condition: Breast Cancer Her2 Expression Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Breast Cancer Her2 Expression

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT07030569A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2)
Phase 3 · 78 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07043725Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
Phase N/A · 26 location(s) · Sun Yat-sen University · NCT06551220The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T
Phase N/A · 1 location(s) · Shandong Cancer Hospital and Institute · NCT07376174Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Br
Phase 2 · 72 location(s) · MedSIR · NCT06486883A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NA · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06127979Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05769010Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
NA · 1 location(s) · University of Rochester · NCT07630402Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
NA · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06909604A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrin
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06656624Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Phase 3 · 3 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05904964Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
NA · 1 location(s) · Fudan University · NCT04281641Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
Phase N/A · 1 location(s) · The Affiliated Hospital of Qingdao University · NCT06916637A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06439771A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05911958A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other
Phase 1 · 7 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05461768HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Phase N/A · 1 location(s) · Renske Altena · NCT06830382Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced
Phase 4 · 11 location(s) · Institut Claudius Regaud · NCT07195344To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Phase N/A · 1 location(s) · Fondazione Sandro Pitigliani · NCT04660435HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer
NA · 1 location(s) · Imperial College London · NCT03827317HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
Phase N/A · 1 location(s) · Fudan University · NCT07586215A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07497386A Composite Assay for HER2-positive Early-stage Breast Cancer Management
Phase N/A · 2 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06762977Validation of the Oncoliq Test for the Early Detection of Breast Cancer.
Phase N/A · 1 location(s) · Oncoliq US Inc · NCT07331506
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.